AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23942975 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lens with chiseled edge design
Number of subjects: 26
Study 23942975 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lens with knife edge design
Number of subjects: 26
Study 23942975 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lens with plano midperipheral shape profile
Number of subjects: 26
Study 23942975 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lens with different edge designs
Number of subjects: 26
Study 23942975 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lens with midperipheral shape profile
Number of subjects: 26
Study 23942975 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lens with edge design
Number of subjects: 26
Study 22216653 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice 1 (0.3% triclosan, 2.0% PVM/MA copolymer, 0.243% sodium fluoride, specially-designed silica)
Number of subjects: 118
Study 22216653 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice 2 (0.454% stannous fluoride, sodium hexametaphosphate, zinc lactate)
Number of subjects: 118
Study 22216653 — intervention group
Group type: COMPARATOR
Intervention: Negative Control Dentifrice (0.243% sodium fluoride)
Number of subjects: 118
Study 19798634 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release acipimox capsules
Number of subjects: 0
Study 19798634 — intervention group
Group type: COMPARATOR
Intervention: Sodium salt form of acipimox
Number of subjects: 0
Study 19798634 — intervention group
Group type: COMPARATOR
Intervention: Free acid form of acipimox
Number of subjects: 0
Study 19798634 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration to the colon
Number of subjects: 0
Study 16820995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol (45 mg/day)
Number of subjects: 54
Study 16820995 — intervention group
Group type: COMPARATOR
Intervention: Carbocisteine (1500 mg/day)
Number of subjects: 54
Study 16820995 — intervention group
Group type: COMPARATOR
Intervention: Rebamipide (300 mg/day)
Number of subjects: 54
Study 12631533 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral-redundant stimulus pairs (Go-Both Task)
Number of subjects: 20
Study 12631533 — intervention group
Group type: EXPERIMENTAL
Intervention: Redundant target stimuli (Go/No-Go Task)
Number of subjects: 20
Study 10853205 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lung hyperinflation treatment (patient positioning, suctioning, and manual lung hyperinflation)
Number of subjects: 18
Study 10853205 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lung hyperinflation treatment
Number of subjects: 18
Study 10853205 — intervention group
Group type: COMPARATOR
Intervention: Side-lying treatment (patient positioning and suctioning)
Number of subjects: 18
Study 9489064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate plus calcium supplementation
Number of subjects: 55
Study 9489064 — intervention group
Group type: COMPARATOR
Intervention: Continuous calcium supplementation
Number of subjects: 55
Study 8096526 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone 2 mg/day increasing to 12 mg/day over 3 weeks
Number of subjects: 21
Study 2869057 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg
Number of subjects: 11
Study 2869057 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg
Number of subjects: 11
Study 2869057 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 11
Study 2869057 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 11
Study 2869057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29934799 — intervention group
Group type: EXPERIMENTAL
Intervention: Black patient with a decayed tooth
Number of subjects: 636
Study 29934799 — intervention group
Group type: EXPERIMENTAL
Intervention: Black patient with an ill-adapted amalgam
Number of subjects: 636
Study 29717839 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Testosterone Undecanoate Capsules (TUC) combined with Qilin Pills (QLP) (6g, tid) for 3 months
Number of subjects: 63
Study 29717839 — intervention group
Group type: COMPARATOR
Intervention: Oral Testosterone Undecanoate Capsules (TUC) (80 mg, qd) for 3 months
Number of subjects: 63
Study 25788231 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR
Number of subjects: 358
Study 25788231 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (including balloon aortic valvuloplasty)
Number of subjects: 358
Study 25788231 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 358
Study 23733499 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (10 W class IV laser, 6.6 ± 1.3 J/cm²)
Number of subjects: 16
Study 23733499 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 16
Study 22117974 — intervention group
Group type: COMPARATOR
Intervention: Molecular target therapy gefitinib (group I)
Number of subjects: 36
Study 22117974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation prior to gefitinib (group II)
Number of subjects: 36
Study 19448045 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 1 (isomaltulose)
Number of subjects: 15
Study 19448045 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 2 (sucromalt)
Number of subjects: 15
Study 19448045 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat formula
Number of subjects: 15
Study 19448045 — intervention group
Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 15
Study 16786395 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical model for non-invasive estimation of AAA wall strength distribution
Number of subjects: 0
Study 16786395 — intervention group
Group type: EXPERIMENTAL
Intervention: Backwards-stepwise regression and linear mixed-effects modeling
Number of subjects: 0
Study 16786395 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstrative application of the model
Number of subjects: 0
Study 15325921 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase and lanoteplase (thrombolytic therapy)
Number of subjects: 147
Study 11230478 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus radiotherapy (CT/RT group)
Number of subjects: 456
Study 11230478 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (RT group)
Number of subjects: 456
Study 9436408 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose levodopa therapy (0.5 mg/kg/day)
Number of subjects: 20
Study 9436408 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study 8056007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridogrel 300 mg i.v. before thrombolytic treatment and 300 mg b.i.d. orally thereafter
Number of subjects: 90
Study 8056007 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ASA 250 mg immediately before thrombolytic treatment and 100 mg once a day orally thereafter
Number of subjects: 90
Study 2691819 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright cycle ergometry (UP)
Number of subjects: 20
Study 2691819 — intervention group
Group type: COMPARATOR
Intervention: Semi-recumbent cycle ergometry (SR)
Number of subjects: 20
Study 4581080 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Sodium (sodium chloride preparation)
Number of subjects: 19
Study 4581080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30586365 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 267
Study 27586506 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (leuprorelin acetate or goserelin acetate)
Number of subjects: 56
Study 27586506 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (degarelix)
Number of subjects: 56
Study 24214840 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC gynecologic cancer education materials
Number of subjects: 1380
Study 23867113 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib plus opioids
Number of subjects: 0
Study 23867113 — intervention group
Group type: COMPARATOR
Intervention: Opioids alone
Number of subjects: 0
Study 20439798 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification-only intervention
Number of subjects: 487
Study 20439798 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 487
Study 20439798 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (educational intervention, identification, both, or no intervention)
Number of subjects: 487
Study 20439798 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline hyperactivity/inattention scores (regardless of intervention)
Number of subjects: 487
Study 19025397 — intervention group
Group type: EXPERIMENTAL
Intervention: Virological arm (VA)
Number of subjects: 121
Study 19025397 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunological arm (IA)
Number of subjects: 121
Study 19025397 — intervention group
Group type: COMPARATOR
Intervention: Control arm (CA)
Number of subjects: 121
Study 19025397 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 121
Study 16523265 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and acupressure at point P6
Number of subjects: 28
Study 16523265 — intervention group
Group type: COMPARATOR
Intervention: Sham point treatment
Number of subjects: 28
Study 14719754 — intervention group
Group type: EXPERIMENTAL
Intervention: Packable resin‐based composite (SureFil)
Number of subjects: 65
Study 14719754 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hybrid resin‐based composite (SpectrumTPH)
Number of subjects: 65
Study 11063446 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved iodine status (increased urinary iodine concentrations)
Number of subjects: 196
Study 11063446 — intervention group
Group type: COMPARATOR
Intervention: Unchanged iodine status (no increase in urinary iodine concentrations)
Number of subjects: 196
Study 8930778 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine solution (1, 2, and 4 mg)
Number of subjects: 171
Study 8930778 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine tablets (1 mg and 2 mg)
Number of subjects: 171
Study 8930778 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of clemastine with phenylpropanolamine
Number of subjects: 171
Study 8930778 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablets (1 mg or 2 mg clemastine + 75 mg phenylpropanolamine)
Number of subjects: 171
Study 1409882 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric isokinetic contractions at velocities of 30, 90, 120, and 180 degrees/s; Eccentric isokinetic contractions at velocities of 30, 90, 120, and 180 degrees/s; Isometric contractions at 40 and 60 degrees of knee flexion.
Number of subjects: 10
Study 1409882 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice protocol developed from initial testing.
Number of subjects: 10
Study 1409882 — intervention group
Group type: EXPERIMENTAL
Intervention: Test and retest sessions.
Number of subjects: 10
Study 3907919 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin plus ticarcillin
Number of subjects: 98
Study 3907919 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin plus ticarcillin
Number of subjects: 98
Study 31194897 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV RNA positive samples
Number of subjects: 38137
Study 31194897 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV IgM positive samples
Number of subjects: 38137
Study 31194897 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV IgG positive samples
Number of subjects: 38137
Study 31194897 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect evidence of recent HEV exposure
Number of subjects: 38137
Study 31194897 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV IgG positive samples in randomly selected samples
Number of subjects: 38137
Study 31194897 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of active HEV infection
Number of subjects: 38137
Study 31194897 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HEV IgG prevalence
Number of subjects: 38137
Study 29288581 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-gauge needle
Number of subjects: 156
Study 29288581 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge needle
Number of subjects: 156
Study 29288581 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-gauge needle
Number of subjects: 156
Study 29288581 — intervention group
Group type: EXPERIMENTAL
Intervention: All needle sizes in hyperechoic nodules
Number of subjects: 156
Study 29288581 — intervention group
Group type: EXPERIMENTAL
Intervention: All needle sizes in hypoechoic nodules
Number of subjects: 156
Study 29288581 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodule size
Number of subjects: 156
Study 26863885 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 14
Study 25354951 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based training (HT)
Number of subjects: 50
Study 25354951 — intervention group
Group type: COMPARATOR
Intervention: Centre-based training (CT)
Number of subjects: 50
Study 23006787 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 18
Study 23006787 — intervention group
Group type: COMPARATOR
Intervention: No Kinesio taping (Control)
Number of subjects: 18
Study 19821225 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (PROT) - 30% protein content, 16.74 MJ
Number of subjects: 10
Study 19821225 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate diet (CHO) - 68% carbohydrate, 16.74 MJ
Number of subjects: 10
Study 19821225 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (PROT)
Number of subjects: 10
Study 19821225 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate diet (CHO)
Number of subjects: 10
Study 19130860 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga training for six weeks
Number of subjects: 46
Study 19130860 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yoga training)
Number of subjects: 46
Study 15990196 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a (40 KD)/ribavirin
Number of subjects: 1121
Study 15990196 — intervention group
Group type: COMPARATOR
Intervention: interferon alfa‐2b plus ribavirin
Number of subjects: 1121
Study 15990196 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1121
Study 12943875 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol or carvedilol for 6 months
Number of subjects: 33
Study 12943875 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 age-matched healthy volunteers)
Number of subjects: 33
Study 12943875 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CHF
Number of subjects: 33
Study 12943875 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockade
Number of subjects: 33
Study 10789958 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 0.3 mg daily (n = 9)
Number of subjects: 18
Study 10789958 — intervention group
Group type: COMPARATOR
Intervention: Hyoscine butylbromide (HB) 60 mg daily (n = 9)
Number of subjects: 18
Study 8872652 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise with thermal clamp (39 degrees C)
Number of subjects: 9
Study 8872652 — intervention group
Group type: COMPARATOR
Intervention: Endurance exercise without thermal clamp (23 degrees C)
Number of subjects: 9
Study 1524042 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by radiotherapy (Group B)
Number of subjects: 42
Study 1524042 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (Group A)
Number of subjects: 42
Study 1524042 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B) with complete response
Number of subjects: 42
Study 1524042 — intervention group
Group type: COMPARATOR
Intervention: Group A (Radiotherapy)
Number of subjects: 42
Study 1524042 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (Induction chemotherapy followed by radiotherapy)
Number of subjects: 42
Study 1524042 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 42
Study 1524042 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen
Number of subjects: 42
Study 3542496 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine therapy (4 X 0.25 mg/d for five days a week)
Number of subjects: 74
Study 3542496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 3542496 — intervention group
Group type: COMPARATOR
Intervention: Colchicine therapy and Placebo
Number of subjects: 74
Study 29902037 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported self-management (SSM) intervention for depression
Number of subjects: 71
Study 25746819 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-micronutrient fortified milk beverage
Number of subjects: 0
Study 25746819 — intervention group
Group type: COMPARATOR
Intervention: Unfortified milk based control drink
Number of subjects: 0
Study 25746819 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 24935757 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 121
Study 22234594 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) training simulator for hysteroscopic placement of tubal sterilization implants
Number of subjects: 46
Study 19117959 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 U/kg unfractionated heparin bolus
Number of subjects: 54
Study 19117959 — intervention group
Group type: COMPARATOR
Intervention: 0 U/kg unfractionated heparin bolus
Number of subjects: 54
Study 19117959 — intervention group
Group type: COMPARATOR
Intervention: 80 U/kg unfractionated heparin bolus
Number of subjects: 54
Study 23756099 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial receptivity array (ERA) guided personalized embryo transfer (pET)
Number of subjects: 110
Study 23756099 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 23756099 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized embryo transfer (pET) after ERA
Number of subjects: 110
Study 23756099 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized embryo transfer (pET) after second ERA
Number of subjects: 110
Study 16416345 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with aMCI
Number of subjects: 107
Study 16416345 — intervention group
Group type: COMPARATOR
Intervention: Patients reporting memory problems without memory deficit
Number of subjects: 107
Study 16416345 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patients reporting memory decline
Number of subjects: 107
Study 16416345 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Number of subjects: 107
Study 16416345 — intervention group
Group type: COMPARATOR
Intervention: Patients with aMCI compared to patients without evident memory impairment
Number of subjects: 107
Study 12858654 — intervention group
Group type: EXPERIMENTAL
Intervention: OCM (omeprazole + clarithromycin + metronidazole)
Number of subjects: 0
Study 12858654 — intervention group
Group type: EXPERIMENTAL
Intervention: RCM (ranitidine + clarithromycin + metronidazole)
Number of subjects: 0
Study 12858654 — intervention group
Group type: EXPERIMENTAL
Intervention: OAM (omeprazole + amoxicillin + metronidazole)
Number of subjects: 0
Study 12858654 — intervention group
Group type: EXPERIMENTAL
Intervention: RAM (ranitidine + amoxicillin + metronidazole)
Number of subjects: 0
Study 10216104 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT3 gene mutation
Number of subjects: 201
Study 10216104 — intervention group
Group type: EXPERIMENTAL
Intervention: N-RAS gene mutation
Number of subjects: 201
Study 10216104 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 60 years or older
Number of subjects: 201
Study 10216104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic data
Number of subjects: 201
Study 10216104 — intervention group
Group type: EXPERIMENTAL
Intervention: FAB types other than M2
Number of subjects: 201
Study 10216104 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocytosis over 100 +/- 10(9)/L
Number of subjects: 201
Study 7618972 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding (clear liquid diet on the first postoperative day followed by a regular diet as tolerated)
Number of subjects: 161
Study 7618972 — intervention group
Group type: COMPARATOR
Intervention: Regular feeding (traditional method, feeding only after resolution of postoperative ileus)
Number of subjects: 161
Study 7618972 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding
Number of subjects: 161
Study 2613390 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadocaine hydrochloride tablet (30 mg t.i.d. for four days)
Number of subjects: 28
Study 2613390 — intervention group
Group type: COMPARATOR
Intervention: Vadocaine hydrochloride solution
Number of subjects: 28
Study 796755 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg chlorpromazine/day
Number of subjects: 55
Study 796755 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg chlorpromazine/day
Number of subjects: 55
Study 796755 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg chlorpromazine‐‐250 mg alpha‐methyldopa/day
Number of subjects: 55
Study 796755 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg chlorpromazine‐‐500 mg alpha‐methyldopa/day
Number of subjects: 55
Study 796755 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg chlorpromazine‐‐750 mg alpha‐methyldopa/day
Number of subjects: 55
Study 31234240 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine (low dose: 40 or 50 mg/day)
Number of subjects: 0
Study 31234240 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine (high dose: 75 or 80 mg/day)
Number of subjects: 0
Study 31234240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27274016 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic notes
Number of subjects: 21
Study 26787182 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (Exacyl, 1.5 g i.v.) before the operation
Number of subjects: 119
Study 26787182 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antifibrinolytic agent)
Number of subjects: 119